HRP20230697T1 - Liječenje karcinoma - Google Patents
Liječenje karcinoma Download PDFInfo
- Publication number
- HRP20230697T1 HRP20230697T1 HRP20230697TT HRP20230697T HRP20230697T1 HR P20230697 T1 HRP20230697 T1 HR P20230697T1 HR P20230697T T HRP20230697T T HR P20230697TT HR P20230697 T HRP20230697 T HR P20230697T HR P20230697 T1 HRP20230697 T1 HR P20230697T1
- Authority
- HR
- Croatia
- Prior art keywords
- erdafitinib
- use according
- fgfr3
- phosphate levels
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
- Laminated Bodies (AREA)
- Prostheses (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455211P | 2017-02-06 | 2017-02-06 | |
| EP17209098 | 2017-12-20 | ||
| PCT/EP2018/052694 WO2018141921A1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
| EP18702299.1A EP3576740B1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230697T1 true HRP20230697T1 (hr) | 2023-10-13 |
Family
ID=61094531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230697TT HRP20230697T1 (hr) | 2017-02-06 | 2018-02-02 | Liječenje karcinoma |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11077106B2 (https=) |
| EP (2) | EP4286005A3 (https=) |
| JP (3) | JP2020505425A (https=) |
| KR (2) | KR20250069693A (https=) |
| CN (1) | CN110198716A (https=) |
| AU (2) | AU2018216969B2 (https=) |
| BR (1) | BR112019016043A2 (https=) |
| CA (1) | CA3049737A1 (https=) |
| DK (1) | DK3576740T3 (https=) |
| ES (1) | ES2953005T3 (https=) |
| FI (1) | FI3576740T3 (https=) |
| HR (1) | HRP20230697T1 (https=) |
| HU (1) | HUE062453T2 (https=) |
| IL (1) | IL268463A (https=) |
| JO (1) | JOP20190190B1 (https=) |
| LT (1) | LT3576740T (https=) |
| MX (2) | MX2019009304A (https=) |
| NZ (2) | NZ796822A (https=) |
| PH (1) | PH12019501885A1 (https=) |
| PL (1) | PL3576740T3 (https=) |
| RS (1) | RS64778B1 (https=) |
| SG (2) | SG11201907199QA (https=) |
| SI (1) | SI3576740T1 (https=) |
| SM (1) | SMT202300233T1 (https=) |
| TW (1) | TWI874925B (https=) |
| UA (1) | UA126336C2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200208224A1 (en) * | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| EP4063516A1 (en) | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| AU2018216969B2 (en) * | 2017-02-06 | 2024-04-11 | Janssen Pharmaceutica Nv | Cancer treatment |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
| AU2020253827B2 (en) * | 2019-03-29 | 2026-01-08 | Janssen Pharmaceutica Nv | FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| SG11202109854RA (en) * | 2019-03-29 | 2021-10-28 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| MX2022009905A (es) * | 2020-02-12 | 2022-08-25 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. |
| WO2021201201A1 (ja) * | 2020-04-03 | 2021-10-07 | インタープロテイン株式会社 | 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物 |
| IL324823A (en) * | 2023-05-24 | 2026-01-01 | Janssen Pharmaceutica Nv | Treatment of locally advanced or metastatic urothelial carcinoma with ardefinitiv |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI719960B (zh) * | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| AU2018216969B2 (en) * | 2017-02-06 | 2024-04-11 | Janssen Pharmaceutica Nv | Cancer treatment |
-
2018
- 2018-02-02 AU AU2018216969A patent/AU2018216969B2/en active Active
- 2018-02-02 SG SG11201907199QA patent/SG11201907199QA/en unknown
- 2018-02-02 RS RS20230615A patent/RS64778B1/sr unknown
- 2018-02-02 SG SG10202105110VA patent/SG10202105110VA/en unknown
- 2018-02-02 MX MX2019009304A patent/MX2019009304A/es unknown
- 2018-02-02 EP EP23178682.3A patent/EP4286005A3/en active Pending
- 2018-02-02 HU HUE18702299A patent/HUE062453T2/hu unknown
- 2018-02-02 JP JP2019541398A patent/JP2020505425A/ja not_active Withdrawn
- 2018-02-02 UA UAA201909567A patent/UA126336C2/uk unknown
- 2018-02-02 PL PL18702299.1T patent/PL3576740T3/pl unknown
- 2018-02-02 DK DK18702299.1T patent/DK3576740T3/da active
- 2018-02-02 JO JOJO/P/2019/0190A patent/JOP20190190B1/ar active
- 2018-02-02 LT LTEPPCT/EP2018/052694T patent/LT3576740T/lt unknown
- 2018-02-02 TW TW112109467A patent/TWI874925B/zh active
- 2018-02-02 CA CA3049737A patent/CA3049737A1/en active Pending
- 2018-02-02 EP EP18702299.1A patent/EP3576740B1/en active Active
- 2018-02-02 KR KR1020257014703A patent/KR20250069693A/ko active Pending
- 2018-02-02 SI SI201830961T patent/SI3576740T1/sl unknown
- 2018-02-02 ES ES18702299T patent/ES2953005T3/es active Active
- 2018-02-02 NZ NZ796822A patent/NZ796822A/en unknown
- 2018-02-02 BR BR112019016043-4A patent/BR112019016043A2/pt not_active Application Discontinuation
- 2018-02-02 CN CN201880008126.XA patent/CN110198716A/zh active Pending
- 2018-02-02 US US16/483,579 patent/US11077106B2/en active Active
- 2018-02-02 FI FIEP18702299.1T patent/FI3576740T3/fi active
- 2018-02-02 KR KR1020197024552A patent/KR20190110581A/ko not_active Ceased
- 2018-02-02 SM SM20230233T patent/SMT202300233T1/it unknown
- 2018-02-02 HR HRP20230697TT patent/HRP20230697T1/hr unknown
- 2018-02-02 NZ NZ755301A patent/NZ755301A/en unknown
-
2019
- 2019-08-04 IL IL268463A patent/IL268463A/en unknown
- 2019-08-05 MX MX2022007955A patent/MX2022007955A/es unknown
- 2019-08-05 PH PH12019501885A patent/PH12019501885A1/en unknown
-
2021
- 2021-06-28 US US17/360,618 patent/US20220110935A1/en not_active Abandoned
-
2022
- 2022-11-28 JP JP2022189239A patent/JP7668777B2/ja active Active
-
2024
- 2024-03-22 AU AU2024201871A patent/AU2024201871B2/en active Active
- 2024-11-11 JP JP2024196985A patent/JP2025024064A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230697T1 (hr) | Liječenje karcinoma | |
| Ueshima et al. | Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma | |
| Kozakiewicz et al. | Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma | |
| Taeger et al. | Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer | |
| Gbolahan et al. | A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma | |
| Hofheinz et al. | Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer | |
| JP2020505425A5 (https=) | ||
| Sahu et al. | Targeted therapy in biliary tract cancers—current limitations and potentials in the future | |
| Shepherd et al. | Angiogenesis inhibitors under study for the treatment of lung cancer | |
| Hescot et al. | Pancreatic atrophy—a new late toxic effect of sorafenib | |
| HRP20211244T1 (hr) | Farmaceutske kompozicije koje sadrže n-(3,5-dimetoksifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)kvinoksalin-6-il]etan-1,2-diamin | |
| CN106822905B (zh) | 含Survivin抑制剂和IRE1抑制剂的药物及用途 | |
| IL252631B1 (en) | ACTIVIN-ACTRII antagonists and uses for the treatment of anemia | |
| US11007194B2 (en) | Method of treating a proliferative disease | |
| Luo et al. | Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2 | |
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| Aparo et al. | Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy | |
| Martina Ferrari et al. | Pyrazolopyrimidine derivatives as antineoplastic agents: With a special focus on thyroid cancer | |
| FI3773595T3 (fi) | Syöpälääkekoostumuksia yhdistelmähoitoon | |
| Jeong et al. | Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation | |
| Maita et al. | Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function | |
| Domagala et al. | Iniparib in metastatic triple-negative breast cancer | |
| NZ786586A (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| CN103251586B (zh) | 抗血管发生药物为基础的抗肿瘤组合物 | |
| Miranda et al. | Targeted fibroblast growth factor receptor (FGFR) inhibition in recurrent, metastatic anal carcinoma: a case report |